Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2014 | Research article

Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment

Authors: Weidong Li, Cihui Chen, Shakir M Saud, Liang Geng, Ge Zhang, Rui Liu, Baojin Hua

Published in: BMC Complementary Medicine and Therapies | Issue 1/2014

Abstract

Background

Lung cancer is one of the leading causes of cancer-related mortality worldwide. Conventional chemotherapy and radiotherapy are the primary therapeutic methods for lung cancer with the use of combination therapies gaining popularity. The frequency and duration of treatment, as well as, managing lung cancer by targeting multiple aspects of cancer biology is often limited by toxicity to the patient. There are many naturally occurring anticancer agents that have a high degree of efficacy and low toxicity, offering a viable and safe approach for the treatment of lung cancer. The herbs traditionally used in Chinese medicine for anticancer treatment offer great potential to enhance the efficacy of conventional therapy. In this study, we evaluated the synergistic effects of Fei-Liu-Ping (FLP) ointment in treating lung cancer; a known anticancer Chinese herbal based formula.

Methods

In this study, A549 human lung carcinoma cell line and Lewis lung carcinoma xenograft mouse model were used. In addition, we utilized an in vitro co-culture system to simulate the tumor microenvironment in order to evaluate the molecular mechanisms of FLP treatment.

Results

FLP treatment significantly inhibited tumor growth in the Lewis lung xenograft by 40 percent, compared to that of cyclophosphamide (CTX) of 62.02 percent. Moreover, combining FLP and CTX inhibited tumor growth by 83.23 percent. Upon evaluation, we found that FLP treatment reduced the concentration of serum pro-inflammatory cytokines IL-6, TNF-α, and IL-1β. In addition, we also found an improvement in E-cadherin expression and inhibition of N-cadherin and MMP9. We found similar findings in vitro when we co-cultured A549 cells with macrophages. FLP treatment inhibited A549 cell growth, invasion and metastasis, in part, through the regulation of NF-κB and altering the expression of E-cadherin, N-cadherin, MMP2 and MMP9.

Conclusions

FLP exerts anti-inflammatory properties in the tumor microenvironment, which may contribute to its anticancer effects. FLP treatment may be a promising therapy for inflammation associated lung cancer treatment alone, or in combination with conventional therapies and may prevent lung cancer metastasis.

Available only for authorised users

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin. 2005, 55 (1): 10-30. 10.3322/canjclin.55.1.10.CrossRefPubMed

Tang JM, He QY, Guo RX, Chang XJ: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006, 51 (2): 181-191. 10.1016/j.lungcan.2005.10.003.CrossRefPubMed

Brekken RA, Thorpe PE: Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 2001, 21 (6B): 4221-4229.PubMed

Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, Sun J, Zhou L, Yao Y, Jiao L, Su W, Guo H, Chen P, Liu J: Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med. 2012, 12: 112-10.1186/1472-6882-12-112.CrossRefPubMedPubMedCentral

Guo H, Liu JX, Xu L, Madebo T, Baak JP: Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther. 2011, 10 (2): 127-137. 10.1177/1534735410387599.CrossRefPubMed

Wan C, You S, Quan P, Song Y, Liu T, Lu J, Zheng P: Development and validation of the quality-of-life assessment system for lung cancer based on traditional Chinese medicine. Evid Based Complement Altern Med. 2012, 2012: 945910-CrossRef

Wong R, Sagar CM, Sagar SM: Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev. 2001, 27 (4): 235-246. 10.1053/ctrv.2001.0227.CrossRefPubMed

Yang D, Tian G: Review of experimental study on treatment of lung cancer with traditional Chinese medicine. Zhongguo Zhong Yao Za Zhi. 2009, 34 (18): 2405-2409.PubMed

Zhang P, Piao B, Sun G: Influence of feiliuping No. 2 on platelet surface glycoprotein expression in mid-late stage lung cancer patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000, 20 (1): 31-33.PubMed

10.

Zheng HG, Piao BK, Hua BJ: Effect of feiliuping ointment and its disassembled prescriptions on dendritic cell of mice with transplanted Lewis lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010, 30 (12): 1288-1291.PubMed

11.

Coussens LM, Zitvogel L, Palucka AK: Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science. 2013, 339 (6117): 286-291. 10.1126/science.1232227.CrossRefPubMedPubMedCentral

12.

Candido J, Hagemann T: Cancer-related inflammation. J Clin Immunol. 2013, 33 (Suppl 1): S79-84.CrossRefPubMed

13.

Bochu W, Liancai Z, Qi C: Primary study on the application of serum pharmacology in Chinese traditional medicine. Colloids Surf B: Biointerfaces. 2005, 43 (3–4): 194-197.CrossRefPubMed

14.

Cao Y, Zhang D, Zheng G, Zhang J: Study on effect of drug concentration of "Bushen huayu jiedu fang" drug serum on drug-resistance lung cancer cells with serum pharmacology. Zhong Yao Cai. 2003, 26 (4): 263-265.PubMed

15.

Plezia PM, Alberts DS, Peng YM, Xu MJ, Sayers S, Davis TP, Surwit EA, Meyskens FL: The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. Prev Med. 1989, 18 (5): 680-687. 10.1016/0091-7435(89)90039-X.CrossRefPubMed

16.

Walther H, Meyer FP, Quednow B, Leuschner U, Kohler E, Horenburg I: Dosage monitoring through measurement of serum level–a task of clinical pharmacology. Int J Clin Pharmacol Biopharm. 1978, 16 (8): 387-390.PubMed

17.

Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee BN: Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003, 97 (11): 2919-2925. 10.1002/cncr.11382.CrossRefPubMed

18.

Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Cleeland CS: A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004, 11 (5): 279-292. 10.1159/000079408.CrossRefPubMed

19.

Dantzer R: Cytokine-induced sickness behavior: where do we stand?. Brain Behav Immun. 2001, 15 (1): 7-24. 10.1006/brbi.2000.0613.CrossRefPubMed

20.

Rube CE, Wilfert F, Uthe D, Konig J, Liu L, Schuck A, Willich N, Remberger K, Rube C: Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol. 2004, 72 (2): 231-241. 10.1016/j.radonc.2004.05.004.CrossRefPubMed

21.

Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2 (4): 301-310. 10.1038/nrc780.CrossRefPubMed

22.

Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002, 2 (10): 725-734. 10.1038/nri910.CrossRefPubMed

23.

Birchmeier W, Birchmeier C: Epithelial-mesenchymal transitions in development and tumor progression. EXS. 1995, 74: 1-15.PubMed

24.

Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005, 17 (5): 548-558. 10.1016/j.ceb.2005.08.001.CrossRefPubMed

25.

Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006, 7 (2): 131-142. 10.1038/nrm1835.CrossRefPubMed

26.

Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25 (1): 9-34. 10.1007/s10555-006-7886-9.CrossRefPubMed

27.

Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980, 284 (5751): 67-68. 10.1038/284067a0.CrossRefPubMed

28.

Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C: Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004, 25 (8): 1543-1549. 10.1093/carcin/bgh146.CrossRefPubMed

29.

Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005, 175 (2): 1197-1205. 10.4049/jimmunol.175.2.1197.CrossRefPubMed

30.

Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004, 6 (3): 203-208. 10.1016/j.ccr.2004.09.003.CrossRefPubMed

31.

Aggarwal BB, Vijayalekshmi RV, Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. in Cancer Res. 2009, 15 (2): 425-430.

32.

Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS: Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A. 2007, 104 (47): 18514-18519. 10.1073/pnas.0705316104.CrossRefPubMedPubMedCentral

33.

Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, Fingleton B: Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res. 2008, 6 (3): 364-371. 10.1158/1541-7786.MCR-07-0309.CrossRefPubMed

34.

Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T: Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009, 462 (7269): 104-107. 10.1038/nature08462.CrossRefPubMedPubMedCentral

35.

Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M: Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 2010, 17 (1): 89-97. 10.1016/j.ccr.2009.12.008.CrossRefPubMedPubMedCentral

36.

Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004, 3 (1): 17-26. 10.1038/nrd1279.CrossRefPubMed

37.

Garg A, Aggarwal BB: Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 2002, 16 (6): 1053-1068. 10.1038/sj.leu.2402482.CrossRefPubMed

38.

Zhang Y, Chen F: Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res. 2004, 64 (6): 1902-1905. 10.1158/0008-5472.CAN-03-3361.CrossRefPubMed

39.

Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol. 2002, 3 (3): 221-227. 10.1038/ni0302-221.CrossRefPubMed

40.

Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC: Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 2012, 72 (5): 1290-1300. 10.1158/0008-5472.CAN-11-3123.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/153/prepub

Title: Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment
Authors: Weidong Li
Cihui Chen
Shakir M Saud
Liang Geng
Ge Zhang
Rui Liu
Baojin Hua
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2014
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/1472-6882-14-153

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

In Vitro and In Vivo antifungal activities of selected Cameroonian dietary spices

Antioxidant activities of saponins extracted from Radix Trichosanthis: an in vivo and in vitro evaluation

Complementary medicine in nursing homes - results of a mixed methods pilot study

A randomised multicentre trial of acupuncture in patients with seasonal allergic rhinitis – trial intervention including physician and treatment characteristics

Immunomodulatory effect of an isolated fraction from Tinospora crispa on intracellular expression of INF-γ, IL-6 and IL-8

Dendropanax morbifera Léveille extract facilitates cadmium excretion and prevents oxidative damage in the hippocampus by increasing antioxidant levels in cadmium-exposed rats